Caris Life Sciences, Inc. (CAI) Earnings
Caris Life Sciences, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Nov 4, 2026
From the latest earnings 8-K
Revenue • FY2025
$812.03M
As reported
Diluted EPS • FY2025
-$3.22
As reported
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from CAI's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $812.03M | -$68.09M | — | -$3.22 | $66.89M | 5.6% | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Nov 4, 2026 | 8-K (2.02) | 0002019410-26-000067EDGAR |
| Aug 5, 2026 | 8-K (2.02) | 0002019410-26-000053EDGAR |
| May 7, 2026 | 8-K (2.02) | 0002019410-26-000040EDGAR |
| Feb 26, 2026 | 8-K (2.02) | 0002019410-26-000011EDGAR |
| Jan 12, 2026 | 8-K (2.02) | 0002019410-26-000005EDGAR |
| Nov 5, 2025 | 8-K (2.02) | 0002019410-25-000026EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0002019410-25-000011EDGAR |
Never miss a CAI filing.
Get an email when CAI files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.